Submitted by: Masimo Corporation
2852 Kelvin Ave
Irvine, CA 92614-5826
(714) 250-9688
FAX (714) 250-9686

Company Contact: James J. Cronin, Vice President, Regulatory Affairs/Quality Assurance

Date Summary Prepared: December 5, 2003

Trade Name Masimo SET® Rad-5 Pulse Oximeter
Common Name Pulse Oximeter
Classification Name Oximeter (74DQA) (870.2700)

Substantially Equivalent Devices Masimo SET® Radical Pulse Oximeter with SatShare™ and LNOP series of Sensors and Cables
510(k) Number - K031330

Features and Benefits
- Clinically proven Masimo SET™ technology performance
- Applicable for use on neonate, pediatric and adult patients
- Proven for accurate monitoring in motion and low perfusion environments
- SpO₂, pulse rate, alarm, and perfusion index displays
- Signal IQ™ for signal identification and quality indication
- Lightweight, convenient handheld design
- Long battery life: over 36 hours on 4 “AA” alkaline batteries
- Audible Alarm for sensor-off and low battery
- Alarms for Hi/Low saturation and Hi/Low pulse rate
- FastSat™
- Three sensitivity levels - Max, Normal and APOD™
- Adjustable alarm volume
- Adjustable averaging 2 to 16 seconds

Intended use
The Masimo SET® RAD-5 Pulse Oximeter is intended for continuous noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO₂) and pulse rate (measured by an SpO₂ sensor) for adult, pediatric, and neonatal patients in hospitals, hospital-type facilities, and mobile environments.
510(k) SUMMARY

Indications for use

The Rad-5 Handheld Pulse Oximeter is indicated for the continuous noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO₂) and pulse rate (measured by an SpO₂ sensor). The Rad-5 Handheld Pulse Oximeter is indicated for use with adult, pediatric and neonatal patients during both motion and no motion conditions, and for patients who are well or poorly perfused in hospitals, hospital-type facilities, and mobile environments.

Principles of Operation

The principles of operation of the Masimo SET® Rad-5 pulse oximeter are that oxyhemoglobin and deoxyhemoglobin differ in their absorption of red and infrared light (spectrophotometry), the volume of arterial blood in tissue (and hence, light absorption by that blood) changes during the pulse (plethysmography), and that arterio-venous shunting is highly variable and that fluctuating absorbance by venous blood is a major component of noise during the pulse. Because oxyhemoglobin and deoxyhemoglobin differ in light absorption, the amount of red and infrared light absorbed by the blood is related to hemoglobin oxygen saturation. The Masimo SET® Rad-5 pulse oximeter decomposes the red and infrared pulsatile absorbance signal into an arterial signal plus a noise component and calculates the ratio of the arterial signals without noise. The ratio of the two arterial pulse-added absorbance signals and its value is used to find the SpO₂ saturation in an empirically derived equation into the Masimo SET® Rad-5 software. The values in the look-up table are based upon human blood studies against a laboratory co-oximeter on healthy adult volunteers in induced hypoxia states during motion and non-motion conditions.

Method of Operation

The Masimo SET® Rad-5 pulse oximeter is turned on. An oximetery sensor is attached to a patient’s finger and one end of a patient cable is connected to the sensor and the other end connected to the Rad-5 pulse oximeter.

The monitor will begin continuously displaying the patient’s pulse rate, and SpO₂ value. The practitioner can adjust the high and low alarm limits to their desired value, if required. The practitioner can then use the information that is continuously displayed on the monitor, and hear if an alarm limit is reached, to help assess the condition of the patient and as an aide in determining if any intervention is required by the practitioner.

Once the practitioner determines the patient no longer requires monitoring, the cable is disconnected from the sensor, the oximetry sensor is removed (and disposed of if it is a single use device), and the power to the monitor is turned off.

Power Source

The Masimo SET® Rad 5 pulse oximeter is powered by 4 AA batteries with an operating time of 36 hours.

Specifications and Operating Ranges

<table>
<thead>
<tr>
<th>Range</th>
<th>Saturation (% SpO₂)</th>
<th>1% - 100%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pulse Rate (bpm)</td>
<td>25 - 240</td>
</tr>
<tr>
<td></td>
<td>Perfusion</td>
<td>0.02% - 20%</td>
</tr>
</tbody>
</table>

Accuracy

Saturation (% SpO₂) - During No Motion Conditions

| Adults, Pediatrics | 70% - 100% ± 2 digits |
| 0% - 69% unspecified |
| Neonates           | 70% - 100% ± 3 digits |
| 0% - 69% unspecified |

Saturation (% SpO₂) - During Motion Conditions

| Adults, Pediatrics | 70% - 100% ± 3 digits |
| 0% - 69% unspecified |
| Neonates           | 70% - 100% ± 3 digits |

0021
510(k) SUMMARY

0% - 69% unspecified

Pulse Rate (bpm) - During No Motion Conditions
Adults, Pediatric, Neonates 25 to 240 ± 3 digits

Pulse Rate (bpm) - During Motion Conditions
Adults, Pediatric, Neonates 25 to 240 ± 5 digits

Resolution
Saturation (% SpO2) 1%
Pulse Rate (bpm) 1

Low Perfusion Performance
> 0.02% Pulse Amplitude and % Transmission > 5%
Saturation (% SpO2) ± 2 digits
Pulse Rate ± 3 digits

Interfering Substances
Carboxyhemoglobin may erroneously increase readings. The level of increase is approximately equal to the amount of carboxyhemoglobin present. Dyes, or any substance containing dyes, that change usual arterial pigmentation may cause erroneous readings.

Power
Internally powered by 4 “AA” Alkaline batteries

Isolation
No external power or ground connection, internally powered only

Environmental
Operating Temperature 41°F to + 104°F (5°C to +40°C)
Storage Temperature -40°F to + 158°F (-40°C to +70°C)
Relative Humidity 5% to 95% noncondensing
Operating Altitude 500 mbar to 1060 mbar pressure
-1,000 ft to 18,000 ft (-304 m to 5,486 m)

Circuitry
Microprocessor controlled
Automatic self-test of oximeter when powered on
Automatic setting of parameters
Automatic alarm messages

Display
Type LED, 7-segment
Data Displayed Pulse Rate, SpO2 %, Alarm status, alarm silenced status, Perfusion Index Bar, Signal IQ Bar, Battery Status, APOD, FastSat.

Audio indicators
Adjustable volume audible pulse: OFF and 33% to 100% in 3 steps
Adjustable volume audible alarm tone: levels and 33% to 100% in 3 steps
Alarm silence (120 seconds); all mute (continuous silence)
Pulse rate out-of-limits alarm
SpO2 level out-of limits alarm
Sensor condition alarms
System failure and battery low alarms
Physical characteristics
Dimensions: 6.2" x 3.0" x 1.4" (15.8 cm x 7.6cm x 3.6 cm)
Weight: 13 oz. (0.32 kg)

Modes
Averaging mode: 2, 4, 8, 10, 12, and 16 seconds
Sensitivity Normal, APOD, and MAX

1 The Masimo SET Technology with LNOP Adt sensors has been validated for no motion accuracy in human blood studies on healthy adult volunteers in induced hypoxia studies in the range of 70-100% SpO2 against a laboratory co-oximeter and ECG monitor. This variation equals plus or minus one standard deviation which encompasses 68% of the population.

2 The Masimo SET Technology with LNOP Adt sensors has been validated for motion accuracy in human blood studies on healthy adult volunteers in induced hypoxia studies while performing rubbing and tapping motions, at 2 to 4 Hz at an amplitude of 1 to 2 cm and a non-repetitive motion between 1 to 5 Hz at an amplitude of 2 to 3 cm in induced hypoxia studies in the range of 70-100% SpO2 against a laboratory co-oximeter and ECG monitor. This variation equals plus or minus one standard deviation which encompasses 68% of the population.

3 The Masimo SET Technology with LNOP Neo and Neo Pt sensors has been validated for neonatal motion accuracy in human blood studies on neonates while moving the neonate’s foot at 2 to 4 Hz at an amplitude of 1 to 2 cm against a laboratory co-oximeter and ECG monitor. This variation equals plus or minus one standard deviation which encompasses 68% of the population.

4 The Masimo SET Technology has been validated for low perfusion accuracy in bench top testing against a Biotek Index 2 simulator and Masimo’s simulator with signal strengths of greater than 0.02% and a % transmission of greater than 5% for saturations ranging from 70 to 100%. This variation equals plus or minus one standard deviation which encompasses 68% of the population.

5 This represents approximate run time at lowest indicator brightness, using a new, fully charged battery.

Environmental Testing
Applicable environmental testing per the Reviewers Guidance for Premarket Submissions - November 1993, i.e. electrical, mechanical and environmental were performed and all tests passed.

Nonclinical tests performed that support a determination of substantial equivalence.

The Masimo SET® Rad-5 Pulse Oximeters was subjected to bench testing using a simulator that determined the performance accuracy of the instruments against the simulator under the range of saturation and pulse rates that both devices specify.

The results of the bench testing showed that the Masimo SET® Rad-5 Pulse Oximeters returned the same saturation accuracy values within ± 2 digits and pulse rate values within ± 3 digits when compared to the simulators used.

Clinical tests performed that support a determination of substantial equivalence.

Clinical studies were performed using the Masimo SET® technology on healthy adult volunteer subjects during no motion and motion conditions who were subjected to a progressive induced hypoxia and measuring the arterial hemoglobin saturation value with the instruments against the arterial hemoglobin oxygen determined from arterial blood samples with a CO-Oximeter.

Clinical studies were performed using the Masimo SET® technology on neonates during no motion and motion conditions and measuring the arterial hemoglobin saturation value with the instruments against the arterial hemoglobin oxygen determined from arterial blood samples with a CO-Oximeter.

Clinical studies were performed using the Masimo SET® technology on healthy adult volunteer subjects who were subjected to low perfusion conditions and to a progressive induced hypoxia and measuring the arterial hemoglobin saturation value with the instruments against the arterial hemoglobin oxygen determined from arterial blood samples with a CO-Oximeter.
Clinical studies were performed using the Masimo SET® technology on neonates with low perfusion conditions and measuring the arterial hemoglobin saturation value with the instruments against the arterial hemoglobin oxygen determined from arterial blood samples with a CO-Oximeter.

Clinical studies were conducted following regulations under Title 21 of the Code of Federal Regulations (21 CFR), Part 812 - Investigational Device Exemptions, Part 50 - Protection of Human Subjects and Part 56 - Institutional Review Boards.

The results from the clinical studies show that the Masimo SET® technology saturation accuracy values for adults and pediatrics within ± 2 digits during no motion conditions and ± 3 digits during motion conditions when compared to the CO-Oximeter and the pulse rate accuracy values within ± 3 digits during no motion conditions and ± 5 digits during motion conditions when compared to the ECG.

The specified saturation accuracy from 70% - 100% for neonates is based on the results from clinical studies on neonates with saturations down to 83% combined with clinical studies on adults to show that the Masimo SET® technology to be within ± 3 digits during both motion and no motion conditions when compared to the CO-Oximeter, and the pulse rate accuracy values for neonates to be within ± 3 digits during no motion and ± 5 digits during motion conditions when compared to the ECG.

Conclusions

The results of the environmental testing demonstrated that the Masimo SET® Rad-5Pulse Oximeter met the requirements of Reviewers Guidance for Premarket Submissions - November 1993.

The results of the bench testing demonstrates that the Masimo SET® Rad-5 Pulse Oximeters meet its performance requirements.

The results of the clinical testing demonstrates that the Masimo SET® technology meets its performance requirements during no motion and motion conditions and low perfusion conditions.

The non-clinical and clinical testing performed demonstrates that the Masimo SET® Rad-5 Pulse Oximeters is safe, effective.
Mr. James J. Cronin  
Vice President, Regulatory Affairs/Quality Assurance  
Masimo Corporation  
2852 Kelvin Avenue  
Irvine, California 92614-5826

Re: K033296  
Trade/Device Name: Masimo SET RAD-5 Pulse Oximeter  
Regulation Number: 870.2700  
Regulation Name: Oximeter  
Regulatory Class: II  
Product Code: DQA  
Dated: January 23, 2004  
Received: January 26, 2004

Dear Mr. Cronin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Chiu Lin, Ph.D.
Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Indications for Use

510(k) Number (if known): K033296

Device Name: Masimo SET Rad 5 Pulse Oximeter

Indications For Use:

The Masimo SET® Rad5 Pulse Oximeter is indicated for the continuous noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO₂) and pulse rate (measured by an SpO₂ sensor). The Masimo SET® Rad 5 Pulse Oximeter is indicated for use with adult, pediatric, and neonatal patients during both no motion and motion conditions, and for patients who are well or poorly perfused in hospitals, hospital-type facilities, mobile, and home environments.

Prescription Use ___X___ AND/OR
(Per 21 CFR 801 Subpart D)

Over-The-Counter Use ________
(Per 21 CFR 807 Subpart C)

(Please do not write below this line—continue on another page if needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)

[Signature]
Division Sign-Off
Division of Anesthesiology, General Hospital, Infection Control, Dental Devices

510(k) Number: K033296